Yunnan Energy International Co. Limited Overview
Yunnan Energy International is a micro-cap, Hong Kong-headquartered, Bermuda-incorporated listed platform controlled (73.05%) by Yunnan Provincial Energy Investment Group, a provincial state-owned enterprise owned by the Yunnan SASAC. Originally Techcomp, a laboratory and analytical instrument distributor founded in 1988, the company was taken over in 2018, divested its legacy instrument operating group, and was rebuilt as the parent group's offshore-listed trading and investment vehicle. Today it runs two thin-margin businesses with only 22 employees: (i) a medical and laboratory equipment distribution business serving Grade 3A hospitals in Yunnan and Guizhou; and (ii) a commodity supply-chain (trading) business in coal, photovoltaic modules, silicon materials, Panax notoginseng and stainless steel, increasingly export-oriented. It also holds a 6.67% stake in a parent-group solar and energy-storage project (Dayao Green Energy). Its strategic narrative is to become the group's vehicle for Southeast Asian green-energy investment and cross-border energy supply chain.
Company's own description (latest filings)
Per the FY2025 RA and 1H2026 IA, the Group's principal activities are: (1) the provision of distribution and after-sales services in the PRC for analytical instruments — expressly including medical CT equipment, MRI systems, fully automated microbial mass spectrometers, digital choledochoscopes, colour ultrasound machines, radio-frequency therapeutic devices, anaesthesia machines, patient monitors, and life-science and general laboratory instruments, with specialised and customised hardware and software (the Distribution Business); and (2) trading and supply-chain business on commodities, diversified industrial and consumer products (the Supply Chain Business). In addition, the company describes an International Energy Project Investment strategic pillar, currently expressed through a 6.67% equity interest in YEIG Dayao Green Energy Generation Co., Ltd.
Business model and revenue model
| Revenue type | FY2025 share | Notes |
|---|---|---|
| Product sales (trading/distribution) | 100% | All point-in-time sale of goods (FY2025 RA) |
| Services | — | After-sales embedded in Distribution contracts |
| Subscription / licensing | 0% | — |
| Investment income (non-revenue) | Dividend income HK$0.65M FY2025; HK$4.62M 1H2026 | Booked in other income |
Both segments operate an asset-light procure-to-order intermediary model: the Group identifies customer requirements (specification, affordability), sources from multiple suppliers, and on-sells. 100% of revenue in FY2024 and FY2025 was sale of goods recognised at a point in time (FY2025 RA, note 4). There is no recurring subscription, licensing or separately reported service revenue; after-sales services (testing, training, maintenance) in Distribution are bundled into equipment contracts rather than separately disclosed.
Value chain position
The company sits in the mid-stream distribution/trading layer. It owns no manufacturing, R&D, logistics fleet or brands. Its value-add claimed in Distribution is technical: system-specification design, formulation of testing-standard requirements against customer budgets, installation, and on-site after-sales service. In Supply Chain, its value-add is sourcing, customs clearance capability, financing of working capital (receivables of 60–150 days), and access — via the parent group — to state-owned counterparties and Yunnan-produced commodities (silicon materials, coal, Sanqi/Panax notoginseng).
Customer types and end-markets
Distribution: hospitals (notably Grade 3A public hospitals in Yunnan and Guizhou), universities, research institutes, bureaus of geology and mineral resources, industrial enterprises and government agencies; all customers in FY2025 and 1H2026 were PRC end-users or distributors (FY2025 RA; 1H2026 IA).
Supply Chain: state-owned enterprises and industrial companies — coal users (power plants, the "Jiehua Plant", PetroChina), global silicon-materials customers (Europe, Americas, APAC, Latin America), PV module buyers (including exports to Vientiane, Laos), Vietnamese stainless steel pipe processors, Yunnan Sanqi traders and pharmaceutical companies (1H2026 IA).
Independent characterisation
Analytically, YEIG is best described as a state-sponsored trading shell with an optional green-energy investment angle, rather than an instrument company (the market-data sector tags of "Scientific & Technical Instruments" are a legacy of Techcomp). Gross margins of 3–6% (rising to 10.8% in 1H2026), very high customer concentration (three customers = 59% of FY2025 revenue), funding largely from the parent group, and only 22 staff indicate a business whose economics depend on (a) the parent's counterparty network, (b) related-party credit, and (c) the ability to source higher-margin Yunnan-produced industrial materials (silicon) under connected-transaction frameworks. The 6.67% Dayao stake, while small, now accounts for 18.7% of total assets and generated more pre-tax profit contribution in 1H2026 (HK$4.62M dividend) than half the group's segment result.
Strategy
Stated strategy themes (FY2025 RA and 1H2026 IA, paraphrased)
-
Dual-engine core: keep focusing simultaneously on Distribution and Supply Chain to expand scale and customer base.
-
"Quality and quantity" trading (2026): strengthen collaboration, stabilise scale, control risk, raise profitability; coal, new materials (silicon) and energy-project procurement are designated "core engines".
-
Parent-group leverage: use Yunnan Energy Group's networks, overseas offices, energy-industry experience and brand — including collaboration with Yunnan Province's 12 overseas business representative offices and "Belt and Road"/RCEP positioning.
-
International energy project investment: build on Dayao experience to pursue green-energy (PV, hydropower) projects in Yunnan and Southeast Asia, particularly Laos and Myanmar, and use supply-chain capability to serve parent-group overseas energy infrastructure.
-
Risk and working-capital discipline: manage "two funds" (receivables and inventory), tiered collection strategy, differentiated customer credit policies.
Initiatives in the last 24 months
| Initiative | Date | Detail | Status | Source |
|---|---|---|---|---|
| Dayao Green Energy stake | Jan–Mar 2024; top-ups 2025, 1H2026 | 6.67% stake; RMB50M contribution commitment; aggregate cost HK$55.3M at 30 Jun 2026 | Completed; dividends flowing | FY2024 RA; 1H2026 IA |
| Silicon Master Purchase Agreement | 14 Jan 2026 (SGM 27 Feb 2026) | Secured supply of organic/industrial silicon from Yunnan Energy New Materials Group; caps approx. HK$172.0M p.a. FY2026–27 | Executing; key 1H2026 driver | FY2025 RA |
| Silicon export programme | 2025–2026 | Trial exports to India, Belgium, S. Korea, UK, Brazil; sales to Italy, Japan; exhibited at organosilicon show (Amsterdam) and 2026 Indonesia International Fine Chemicals Exhibition | Ongoing | FY2025 RA; 1H2026 IA |
| Southeast Asian supply-chain nodes | Announced FY2025 RA | Nodes in Laos, Vietnam, Singapore | Planned | FY2025 RA |
| Direct hospital tendering | 2024–2026 | Moved from intermediated sales to direct public-hospital bidding; RMB10M won FY2025; >RMB15M won 1H2026 | Ongoing | FY2025 RA; 1H2026 IA |
| Coal long-term supply | 2025–2026 | Jiehua Plant (>400kt cumulative); PetroChina 42,100 t anthracite | Ongoing | 1H2026 IA |
| Laos PV module exports | 2024–2026 | Exports to Vientiane linked to energy projects | Ongoing | FY2024 RA; 1H2026 IA |
| Laos/Myanmar green energy pipeline | 2024–2026 | Feasibility studies, government liaison, PV and hydropower negotiations | Pre-investment | FY2025 RA; 1H2026 IA |
| Exhibition agency role | 2,026 | Selected as third-party organiser/exhibitor agency for key Yunnan overseas exhibitions | Awarded | 1H2026 IA |
| Bye-law modernisation | Proposed 25 Mar 2026 | Align with HKEX Core Shareholder Protection Standards (hybrid/virtual meetings, e-voting) | For 2026 AGM | FY2025 RA |
Sustainability/ESG commitments and cost programmes
No quantified emissions or cost-reduction targets are disclosed. Admin expense reductions (−2.3% FY2025; −4.2% 1H2026) are attributed to lower legal and professional fees, not a formal programme.
Medium-term targets/guidance
The company issues no numerical financial guidance. The only quantified operational targets are: ≥RMB30M new Distribution contracts in 2H2026, and (prior year) an increase in new contracts in 2026 versus 2025 (1H2026 IA; FY2025 RA). The silicon MPA caps (approx. HK$172M p.a.) indirectly bound the scale of that sourcing channel.
Products & Services
The company does not own brands; it distributes and trades third-party products. Pricing is contract-by-contract (public tender for hospitals; negotiated or tendered for commodities). No list pricing is disclosed.
Distribution Business — medical and laboratory equipment
| Product category | Description / capability | Target customer | Evidence year | Pricing model |
|---|---|---|---|---|
| Medical CT equipment | Computed tomography systems | Grade 3A hospitals | FY2024–1H2026 descriptions | Public tender |
| MRI systems | Magnetic resonance imaging (contracts signed FY2023–FY2024) | Grade 3A hospitals | FY2023, FY2024 RAs | Public tender |
| Linear accelerators | Radiotherapy accelerators | Hospital oncology | FY2023, FY2024 RAs | Public tender |
| Fully automated microbial mass spectrometry detection systems | Microbial identification by mass spectrometry | Hospital labs | FY2023–FY2025 | Tender |
| Colour Doppler ultrasound diagnostic systems | Imaging | Hospitals | FY2023–1H2026 | Tender |
| Endoscopy: electronic bronchoscopes, electronic gastrointestinal endoscopes, laparoscopes, digital choledochoscopes | Minimally invasive diagnostics | Hospitals | FY2023–1H2026 | Tender |
| Pulmonary function detection | Respiratory diagnostics | Hospitals | FY2023, FY2024 | Tender |
| Biological stimulation feedback instruments | Rehabilitation/neuro | Hospitals | FY2023, FY2024 | Tender |
| Immunoassay analysers; blood typing analysers | In-vitro diagnostics | Hospital labs | FY2025 RA | Tender |
| X-ray systems; medical angiographic X-ray systems | Imaging | Hospitals | FY2025 RA; 1H2026 IA | Tender |
| Anaesthesia machines; ventilators; patient/life monitors | Critical care | Hospitals | FY2024–1H2026 | Tender |
| Neurology microscopes; intra-aortic balloon pumps | Surgical/cardiac | Hospitals | 1H2026 IA | Tender |
| Operating room, disinfection centre, medical examination centre equipment | Turnkey departmental fit-outs | Hospitals | 1H2026 IA | Tender |
| Rehabilitation equipment; surgical laboratory equipment | Rehab and surgery | Hospitals | FY2025 RA | Tender |
| Radio-frequency therapeutic devices | Therapy | Hospitals | FY2024–1H2026 | Tender |
| Legacy analytical instruments: chromatographs, spectrophotometers, electron microscopes, general lab instruments | Scientific analysis and testing, with customised hardware/software | Universities, research institutes, geology bureaus, industry | FY2023 RA | Negotiated |
| After-sales services | Testing, training, maintenance, installation, system specification design | All distribution customers | All years | Bundled |
| Metric | FY2023 | FY2024 | FY2025 | 1H2026 |
|---|---|---|---|---|
| Distribution sales contracts (cumulative/new) | approx. HK$110M signed by end-2023 | HK$55.9M signed by end-2024 | RMB38M new contracts; RMB10M direct hospital bids won | >10 hospital bids won, >RMB15M; >RMB30M under bid; ≥RMB30M tracked |
Named supplier brands the company cites experience with: Thermo Fisher, Olympus, Philips and "GM" (as written in filings; likely GE) (FY2023 RA, FY2024 RA).
Order-book indicators:
Sources: FY2023, FY2024, FY2025 RAs; 1H2026 IA. Management target: ≥RMB30M new contracts in 2H2026.
Supply Chain Business — commodity and product lines
| Product line | Description / route | Customers / geography | Period active | Disclosed economics |
|---|---|---|---|---|
| Silicon materials (organosilicon, industrial silicon) | Sourced from Yunnan Energy New Materials Group under Master Purchase Agreement (caps approx. HK$172.0M p.a. FY2026–27); exported | Global silicon-materials customers; trial exports to India, Belgium, South Korea, UK, Brazil; sales also to Italy, Japan | FY2025–present | Higher-margin driver of 1H2026 GP margin of 10.8% |
| Photovoltaic modules / energy storage equipment | Domestic trading and exports to Vientiane, Laos (linked to energy projects) | PV developers, Laos projects | FY2024–present | Key 1H2026 growth driver |
| Coal (pulverized coal, anthracite) | Domestic supply to power plants/industry under "demand forecasting–resource locking–flexible supply" mechanism | Jiehua Plant (>400,000 t pulverized coal cumulative); PetroChina bid won for 42,100 t anthracite | FY2024–present | Freight drove S&D expenses +88% FY2025 |
| Panax notoginseng (Sanqi, TCM herb) | Domestic trading, inventory-holding | Yunnan Sanqi traders; pharma companies | FY2023–present | FY2023 revenue HK$77.0M at 2.1% GM; inventory run-down 2025–26 |
| Stainless steel coils, raw materials and production equipment | Export to Vietnam | Vietnamese stainless pipe processors | FY2022–present | FY2023 sales approx. HK$40.9M at 0.5% GM |
| Towers and wire | Export to Laos (14 batches FY2023) | Laos power infrastructure | FY2023 | HK$14.9M at 8.7% GM |
| Fertilizer | Export to Laos (660 t FY2023) | Laos agriculture | FY2023 | HK$3.0M at 3.3% GM |
| Electrolytic copper (re-export) and copper concentrate | Re-export and domestic trading | — | FY2023–FY2025 (scaled down for risk in 2025) | FY2023 copper concentrate HK$44.8M at 2.9% GM |
| Coffee powder/beans | Yunnan domestic trading | Yunnan coffee traders | FY2022–FY2023 | FY2023 HK$61.5M at 4.6% GM |
| Rubber | Domestic trading | — | FY2023–FY2024 | FY2023 HK$23.3M at 2.6% GM |
| Phosphate rock | Domestic trading | — | FY2023 | HK$10.1M at 2.0% GM |
| Steel products; construction materials | Domestic trading (original 2020 supply-chain line) | Construction | FY2020–FY2023 | FY2023 HK$3.2M |
| Electrolytic devices; misc. export contracts | Exports | — | FY2023 | HK$2.3M and HK$2.9M |
| Medical devices (trading) | Cross-border medical supply chain | — | Planned/ongoing | Not quantified |
| Exhibition agency services | Selected as third-party organiser/exhibitor agency for key Yunnan overseas exhibitions | Yunnan government programmes | 2,026 | Not quantified |
Source for FY2023 product economics: FY2023 RA business review (the most granular product-level disclosure available). FY2024–1H2026 product splits are qualitative only.
Investment holding
| Asset | Description | Carrying value |
|---|---|---|
| 6.67% of YEIG Dayao Green Energy Generation Co., Ltd. | Six PV stations (approx. 523 MW installed as of end-2024) in Dayao County, Yunnan, plus a 300MW/600MWh energy-storage project (capacity leasing and storage power sales) | HK$58.34M FVOCI at 30 Jun 2026 (18.7% of total assets) |
Financial Narrative
Income statement: notes and sources
Sources: FY2023 RA (FY2022/23), FY2024 RA, FY2025 RA; FY2021 revenue and PBT from FY2022 RA comparatives; FY2021 net loss HK$26.952M from aggregator (Stoxray), consistent with the HK$27.0M stated in the FY2022 Annual Report; FY2021 EPS analyst-derived (26.952/275.437). The company reports EPS of HK3.2 cents loss (FY2022) and HK1.8 cents loss (FY2023) to one decimal. EBIT and EBITDA are analyst-derived (PBT plus finance costs; plus D&A) and include other income and impairments.
Margins and growth (analyst-derived)
FY2021 gross margin of 3.7% is as stated in the FY2022 Annual Report chairman's statement. The company reports FY2023 gross margin as 3.0% (rounded).
Revenue CAGR: FY2021–FY2025 four-year CAGR = 47.0% (from a very depressed COVID-era base); FY2022–FY2025 three-year CAGR = 10.9%; FY2019–FY2025 six-year CAGR = 3.9% (HK$311.5M to HK$392.7M) — the latter is the more honest measure of franchise growth since the takeover.
Commentary. The P&L tells a story of a platform rebuilt from near-zero. After the 2018 carve-out of the Techcomp instrument group and the 2020 COVID collapse (revenue HK$61.0M, loss HK$62.2M), revenue was rebuilt almost entirely through low-margin trading, peaking at HK$576.6M in FY2024. The FY2025 contraction (−31.9%) was a deliberate de-risking: management cut Sanqi exposure as demand fell and reduced electrolytic copper volumes under "tightened risk assessment measures" (FY2025 RA). Encouragingly, gross margin rose in each of FY2024 (5.2%), FY2025 (6.3%) and 1H2026 (10.8%), reflecting mix shift toward PV modules and silicon materials. However, the business's structural problem is visible below gross profit: a fixed admin base of about HK$12.7–13.7M, finance costs of HK$3–4M on parent-group loans, and a high PRC tax charge (25% on profitable PRC subsidiaries, with losses elsewhere unrelieved) left FY2025 with a net loss despite positive pre-tax profit. FY2025's effective tax rate exceeded 100%, including a HK$0.966M prior-year under-provision.
Latest interim
1H2026 net profit of HK$8.53M is already larger than any full-year result since the 2018 takeover. Roughly 46% of 1H2026 pre-tax profit came from the Dayao dividend (HK$4.62M of HK$10.04M).
Balance sheet
Sources: FY2023, FY2024, FY2025 RAs. Debt composition FY2025: bank borrowings HK$71.965M, loan from fellow subsidiary HK$60.291M (current), loan from immediate holding company HK$11.764M (non-current); all RMB, fixed rates 2.76–3.29% (FY2025 RA). FY2024 debt was entirely a fellow-subsidiary loan at 2.5%; FY2023 entirely an intermediate-holdco loan at 4% (FY2024 RA).
1H2026 balance sheet (1H2026 IA): total assets HK$312.455M; cash HK$55.582M; trade receivables HK$110.818M; inventories HK$3.133M; FVOCI HK$58.337M; bank borrowings HK$45.971M; holdco loan HK$12.414M; fellow-subsidiary loan repaid to nil; total debt HK$58.385M; net debt HK$2.803M; equity HK$181.424M; gearing 32.2%; current ratio 2.1.
Commentary. The balance sheet has no goodwill, negligible fixed assets (PP&E HK$0.07M) and is essentially a working-capital book funded by the parent. Two points stand out. First, receivable quality deteriorated sharply in FY2025: receivables aged 121–365 days rose from HK$9.7M to HK$50.1M and >365 days from HK$3.1M to HK$8.2M (FY2025 RA note 12). Although receivables halved in 1H2026, the ageing profile worsened further in mix — HK$28.4M is now 1–2 years old and only HK$17.0M is under 90 days (1H2026 IA note 14). Second, the dramatic deleveraging in 1H2026 (gearing 85.6% to 32.2%) was achieved by collecting receivables and liquidating Sanqi inventory, not by retained earnings, so it may partly reverse as volumes rebuild.
Cash flow
Capex from RA notes on PP&E additions. Dayao FY2024 figure is the initial carrying value (cost implied by FY2025 aggregate cost of HK$52.229M less FY2025 addition); a further HK$3.946M was invested in 1H2026 via dividend reinvestment. No buybacks in FY2023–1H2026 (RAs).
Ratios (analyst-derived)
Net debt/EBITDA is not meaningful for FY2022–FY2023 (net cash, negative EBITDA). Current ratios as reported by the company.
Commentary. Returns on capital are negligible (ROIC under 2%) even in the best years, and leverage relative to earnings power (net debt/EBITDA approx. 14x in FY2024–25) would be untenable for a stand-alone trading company; it is sustainable only because lenders are the parent group or banks relying on parent support. The FY2025 cash conversion cycle of 128 days, with DSO near 190 days, is a red flag for a commodity trader. The 1H2026 normalisation (receivables down 46%) improves this materially if sustained.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment revenue (HKD Mn)
| Segment revenue (HKD Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Distribution Business (HKD Mn) | 12.518 | 7.860 | 57.257 | 52.085 | 52.045 |
Supply Chain Business (HKD Mn) | 71.588 | 280.229 | 284.606 | 524.530 | 340.628 |
Total revenue (HKD Mn) | 84.106 | 288.089 | 341.863 | 576.615 | 392.673 |
Results by Segment
| Segment result (HKD Mn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Distribution Business result (HKD Mn) | 1.214 | -1.759 | -1.174 | -1.154 |
Supply Chain Business result (HKD Mn) | -4.326 | 5.613 | 12.358 | 11.786 |
Total segment result (HKD Mn) | -3.112 | 3.854 | 11.184 | 10.632 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Metric (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Distribution segment margin (%) | — | 15.4 | -3.1 | -2.3 | -2.2 |
Supply Chain segment margin (%) | — | -1.5 | 2.0 | 2.4 | 3.5 |
Distribution YoY revenue growth (%) | -77.5 | -37.2 | 628.5 | -9.0 | -0.1 |
Supply Chain YoY revenue growth (%) | 1,233.3 | 291.4 | 1.6 | 84.3 | -35.1 |
Distribution % of revenue (%) | 14.9 | 2.7 | 16.7 | 9.0 | 13.3 |
Supply Chain % of revenue (%) | 85.1 | 97.3 | 83.3 | 91.0 | 86.7 |
Revenue by Segment and Segment Margins & Growth (%)
| Segment (HKD Mn) | 1H2025 | 1H2026 | YoY % |
|---|---|---|---|
Distribution revenue | 20.661 | 2.940 | -85.8 |
Supply Chain revenue | 131.885 | 155.007 | 17.5 |
Distribution result | -0.215 | -0.077 | — |
Supply Chain result | 1.724 | 8.835 | 412.5 |
Supply Chain segment margin (%) | 1.3 | 5.7 | +4.4 pts |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (HKD Mn) | 84.106 | 288.089 | 341.863 | 576.615 | 392.673 |
Cost of sales (HKD Mn) | — | -274.524 | -331.780 | -546.720 | -368.102 |
Gross profit (HKD Mn) | — | 13.565 | 10.083 | 29.895 | 24.571 |
Other income and gains/losses net (HKD Mn) | — | 3.548 | 2.675 | -5.922 | 1.819 |
Selling and distribution expenses (HKD Mn) | — | -5.470 | -0.902 | -4.201 | -7.894 |
Administrative expenses (HKD Mn) | — | -12.705 | -13.684 | -12.988 | -12.688 |
Impairment (losses)/reversals on financial assets (HKD Mn) | — | -5.305 | 1.275 | -0.406 | 0.391 |
Operating income EBIT incl. other income (HKD Mn) | — | -6.512 | -0.569 | 6.378 | 6.199 |
Depreciation and amortisation (HKD Mn) | — | 0.689 | 0.061 | 0.053 | 0.055 |
EBITDA (HKD Mn) | — | -5.823 | -0.508 | 6.431 | 6.254 |
Finance costs (HKD Mn) | — | -2.365 | -4.059 | -3.133 | -3.578 |
Pre-tax income (HKD Mn) | -26.840 | -8.877 | -4.628 | 3.245 | 2.621 |
Income tax (HKD Mn) | — | 0.000 | -0.342 | -2.754 | -3.519 |
Net income attributable (HKD Mn) | -26.952 | -8.877 | -4.970 | 0.491 | -0.898 |
EPS basic and diluted (HK cents) | -9.79 | -3.22 | -1.80 | 0.18 | -0.33 |
Dividends per share (HK cents) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | 3.7 | 4.7 | 2.9 | 5.2 | 6.3 |
EBIT margin (%) | — | -2.3 | -0.2 | 1.1 | 1.6 |
EBITDA margin (%) | — | -2.0 | -0.1 | 1.1 | 1.6 |
Pre-tax margin (%) | -31.9 | -3.1 | -1.4 | 0.6 | 0.7 |
Net margin (%) | -32.0 | -3.1 | -1.5 | 0.1 | -0.2 |
Revenue YoY growth (%) | 37.9 | 242.5 | 18.7 | 68.7 | -31.9 |
Effective tax rate (%) | — | 0.0 | — | 84.9 | 134.3 |
Margin Analysis (%) and Per-Share Data
| Metric | 1H2025 | 1H2026 | YoY % |
|---|---|---|---|
Revenue | 152.546 | 157.947 | 3.5 |
Gross profit | 5.127 | 17.057 | 232.7 |
Gross margin (%) | 3.4 | 10.8 | +7.4 pts |
Other income and gains net | 1.781 | 3.304 | 85.5 |
of which Dayao dividend (net of WHT) | 0.644 | 4.618 | 617.1 |
S&D expenses | -1.803 | -3.782 | 109.8 |
Admin expenses | -5.319 | -5.098 | -4.2 |
Finance costs | -1.756 | -1.444 | -17.8 |
Profit/(loss) before tax | -1.425 | 10.037 | — |
Net profit/(loss) | -2.655 | 8.528 | — |
EPS (HK cents) | -0.96 | 3.10 | — |
Balance Sheet and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (HKD Mn) | — | 221.845 | 318.757 | 414.724 | 450.435 |
Cash and bank balances (HKD Mn) | — | 43.090 | 120.618 | 66.063 | 57.557 |
Trade receivables (HKD Mn) | — | 44.555 | 93.102 | 141.709 | 205.681 |
Inventories (HKD Mn) | — | 23.472 | 40.614 | 72.401 | 40.661 |
Prepayments deposits other receivables (HKD Mn) | — | 110.602 | 64.297 | 93.569 | 92.076 |
Equity investment at FVOCI Dayao (HKD Mn) | 0 | 0 | 0 | 40.877 | 54.390 |
Goodwill and intangibles (HKD Mn) | — | 0 | 0 | 0 | 0 |
Trade payables (HKD Mn) | — | 5.767 | 29.823 | 55.549 | 104.100 |
Short-term debt (HKD Mn) | — | 29.416 | 91.446 | 153.752 | 132.256 |
Long-term debt (HKD Mn) | — | 0 | 0 | 0 | 11.764 |
Total debt (HKD Mn) | — | 29.416 | 91.446 | 153.752 | 144.020 |
Net debt (HKD Mn) | — | -13.674 | -29.172 | 87.689 | 86.463 |
Total equity (HKD Mn) | — | 171.383 | 165.329 | 164.117 | 168.386 |
Working capital net current assets (HKD Mn) | — | 171.257 | 165.203 | 123.135 | 125.690 |
Gearing debt to equity (%) | — | 17.2 | 55.3 | 93.7 | 85.6 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansCash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (HKD Mn) | 77.954 | -66.706 | -7.590 | 14.002 | — |
Capex PP&E additions (HKD Mn) | — | 0.016 | 0.065 | 0.033 | 0.018 |
Free cash flow (HKD Mn) | — | -66.722 | -7.655 | 13.969 | — |
Investment in Dayao equity (HKD Mn) | 0 | 0 | 0 | 40.877 | 11.352 |
Dividends paid (HKD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (HKD Mn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
ROE on average equity (%) | — | -2.95 | 0.30 | -0.54 |
ROA on average assets (%) | — | -1.84 | 0.13 | -0.21 |
ROIC NOPAT at 25% notional tax over equity plus net debt (%) | -3.1 | -0.3 | 1.9 | 1.8 |
Current ratio (x) | 4.4 | 2.1 | 1.5 | 1.5 |
Debt to equity (x) | 0.17 | 0.55 | 0.94 | 0.86 |
Net debt to EBITDA (x) | — | — | 13.6 | 13.8 |
Interest coverage EBIT over finance costs (x) | -2.75 | -0.14 | 2.04 | 1.73 |
Asset turnover on average assets (x) | — | 1.26 | 1.57 | 0.91 |
DSO year-end (days) | 56 | 99 | 90 | 191 |
DIO year-end (days) | 31 | 45 | 48 | 40 |
DPO year-end (days) | 8 | 33 | 37 | 103 |
Cash conversion cycle (days) | 80 | 111 | 101 | 128 |
Region revenue (HKD Mn)
| Region revenue (HKD Mn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
PRC incl. Hong Kong and Macau (HKD Mn) | 130.027 | 277.166 | 367.196 | 253.557 |
Asia excl. PRC (HKD Mn) | 101.303 | 61.819 | 175.514 | 92.377 |
Europe / Other areas (HKD Mn) | 56.759 | 2.878 | 33.905 | 46.739 |
Total (HKD Mn) | 288.089 | 341.863 | 576.615 | 392.673 |
Region growth (%)
| Region growth (%) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
PRC YoY growth (%) | 113.2 | 32.5 | -30.9 |
Asia excl. PRC YoY growth (%) | -39.0 | 183.9 | -47.4 |
Europe/Other YoY growth (%) | -94.9 | 1,078.1 | 37.9 |
PRC share of revenue (%) | 81.1 | 63.7 | 64.6 |
Asia excl. PRC share (%) | 18.1 | 30.4 | 23.5 |
Europe/Other share (%) | 0.8 | 5.9 | 11.9 |
Revenue by Region
| Segment × geography (HKD Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Distribution — PRC (HKD Mn) | 57.257 | 52.085 | 52.045 |
Supply Chain — PRC (HKD Mn) | 219.909 | 315.111 | 201.512 |
Supply Chain — Asia excl. PRC (HKD Mn) | 61.819 | 175.514 | 92.377 |
Supply Chain — Europe/Other (HKD Mn) | 2.878 | 33.905 | 46.739 |
Share Price History
| Date | Price (HKD) | Note | Source |
|---|---|---|---|
Aug–Sep 2018 | 3.267 | Mandatory offer price | SGXNet offer notice |
18 Sep 2025 | 0.98 | — | Stoxray (aggregator) |
9 Mar 2026 | 1.12 | — | etnet |
18 Jul 2026 | 1.20 | Latest verified quote | Investing.com |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
Market cap | HK$330.5M | 275.437M shares × HK$1.20 |
Enterprise value | HK$333.3M |
|
TTM revenue | HK$398.1M | FY2025 − 1H2025 + 1H2026 |
TTM net profit | HK$10.3M | −0.898 + 2.655 + 8.528 |
P/E (TTM) | 32.2x | EPS HK3.73 cents |
EV/EBITDA (TTM) | 19.2x | TTM EBITDA approx. HK$17.4M (incl. dividend income) |
EV/Sales (TTM) | 0.84x | — |
P/B | 1.82x | BVPS HK$0.659 (30 Jun 2026) |
Capital Markets
| Item | Status | Source |
|---|---|---|
Sell-side consensus | None identified (no broker coverage) | — |
Dividend history | Last dividend HK$0.028/share (May 2016, as Techcomp); nil FY2017–1H2026 | Aggregator; RAs |
Dividend policy | No payout policy disclosed; no dividend recommended FY2025, 1H2026 | FY2025 RA; 1H2026 IA |
Buyback authorisation | General mandate typically sought at AGM; no repurchases FY2023–1H2026; no treasury shares | RAs |
Credit ratings (Moody's/S&P/Fitch) | Not rated | — |
Debt maturity | 30 Jun 2026: HK$46.0M bank borrowings due within one year (rates 2.5–3.29% fixed); HK$12.4M holdco loan non-current | 1H2026 IA |
Analyst Conclusions
Management guidance
No numerical guidance. Qualitatively, management expects more Distribution deliveries/acceptances in 2H2026, targets ≥RMB30M new hospital contracts in 2H2026, seeks long-term supply agreements in silicon, PV modules, coal and TCM herbs, and continues pre-investment work on Laos/Myanmar energy projects (1H2026 IA). Consensus: none available.
Bull case
-
Structural margin uplift: the shift to parent-sourced silicon and PV took gross margin to 10.8% in 1H2026; if sustained on roughly HK$400M of revenue, gross profit could approach HK$40M versus a fixed cost base of about HK$13M plus HK$3M of finance costs.
-
Dayao yields and optionality: the investee earned RMB57.8M in FY2025 and declared RMB4.19M to YEIG in 1H2026 alone; further energy-project injections from a large parent could re-rate the vehicle.
-
Balance-sheet repair: gearing fell to 32.2% and receivables halved in six months, reducing financial risk and freeing capacity for growth.
Bear case
-
Related-party dependence: margins hinge on connected-party silicon priced under capped frameworks; profits could be re-allocated within the group at any time.
-
Credit quality: aged receivables (HK$28.4M at 1–2 years) and an RMB21.75M coal advance under enforcement could produce impairments larger than a full year of historical profit.
-
Earnings quality and scale: nearly half of 1H2026 pre-tax profit came from one dividend; trading volumes are concentrated in three customers; and the stock already trades at about 32x TTM earnings and 1.8x book with no dividend.
Catalysts and monitorables (next 12 months)
-
2H2026 Distribution deliveries and FY2026 results (expected ~March 2027).
-
Utilisation of the silicon MPA caps (approx. HK$172M p.a.) and silicon export volumes/prices.
-
Recovery of the coal advance by the 31 Dec 2026 mediation deadline; collection of the US$0.5M factored receivable.
-
Dayao full-year dividend and any further capital calls under the RMB50M commitment.
-
Any definitive agreement on a Laos/Myanmar PV or hydropower investment, or a parent-asset injection.
-
Trajectory of receivable ageing and gearing at FY2026 year-end.
-
Any change in CEO formalisation, auditor, or public-float level.
Analyst verdict
Yunnan Energy International is not, despite its market-data classification, an instrument company; it is a 22-person, state-controlled trading and investment shell whose value lies almost entirely in its relationship with Yunnan Provincial Energy Investment Group. Eight years after acquiring Techcomp at HK$3.267 per share and carving out the operating business, the parent has rebuilt revenue to roughly HK$400M, but cumulative post-takeover earnings remain deeply negative and returns on capital have never exceeded about 2% on an annual basis.
The first half of 2026 marks a genuine inflection: gross margin of 10.8%, net profit of HK$8.5M (already the best result since 2018), receivables nearly halved and gearing cut to 32%. These improvements are real and documented in the 1H2026 interim filing. Yet their sources demand scrutiny. The margin expansion is tied to silicon supplied by a sister company under a connected-transaction framework, and close to half of pre-tax profit was a dividend from a 6.67% stake in a parent-group solar and storage project. The core trading engine remains thin-margin, highly concentrated, and periodically exposed to credit events — the coal prepayment now in court enforcement being the most recent.
At about HK$1.20 the stock trades at roughly 32x trailing earnings and 1.8x book, with no dividend and no broker coverage. That valuation implicitly prices in continued parent support and, more speculatively, future injection of energy assets from Southeast Asia or Yunnan. Investors should treat YEIG as an event-driven option on parent-group corporate actions rather than a fundamentally compounding business. The key tests over the next 12 months are whether 2H2026 sustains double-digit gross margins without the dividend tailwind, whether the coal advance is recovered by the end-2026 deadline, and whether any concrete energy-project transaction is announced. Absent those, the 1H2026 turnaround risks proving cyclical rather than structural.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | On board since | Age / born | Background | Source |
|---|---|---|---|---|---|
Ms. Zhu Yingxue | Chairman (since 6 Jun 2025); Executive Director; Chair of Nomination Committee; CEO 3 Aug 2023 – 6 Jun 2025 | 3 Aug 2023 | 35 at Jun 2025 | Joined Yunnan Energy Investment (HK) Co.; prior management role at Yunnan Energy Investment Foreign Energy Development Co.; Master's in Intercultural Studies (The Chinese University of Hong Kong) | Board change announcements 3 Aug 2023, 6 Jun 2025 |
Mr. Song Henan | Executive Director; Head of Business Development; listed as CEO on etnet market data | 28 Jul 2021 | Born 1993 | Parent-group business development background (details in annual report) | Yahoo Finance; etnet; Webb-site |
Mr. Yang Jie | Executive Director; Chief Financial Officer | 3 Aug 2023 | Born 1977 | Yunnan University business administration (2005); PRC Certified Tax Accountant; prior roles in parent-group entities incl. YEIG International Engineering and Yunneng International Laos Investment | Announcement 3 Aug 2023 |
Mr. Wang Jin | Executive Director | 3 Aug 2023 | 37 at Aug 2023 | Management roles at Yunnan Electric-related entity, Yunnan Energy Financial Services (Mar 2017–Mar 2020), Yunnan Yunneng Asset | Announcement 3 Aug 2023 |
Mr. Shi Fazhen | Independent Non-Executive Director; Chair of Audit and Remuneration Committees | 2018 | 59 (aggregator, c.2023) | — | Investing.com; Directors list 3 Aug 2023 |
Mr. Liu Zongliu | INED; member Audit, Remuneration, Nomination | 29 Nov 2019 | 68 (aggregator, c.2023) | Former official in Foreign Economic Affairs, Yunnan Provincial Department of Commerce; former chairman of a Xiamen company; international trade experience | Board change announcement Nov 2019 |
Ms. Jing Pilin | INED; member Audit, Remuneration, Nomination | 30 Nov 2018 | 72 (aggregator, c.2023) | — | Webb-site; Investing.com |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
12 Apr 2021 | He Junyu resigns as ED | To focus on own business |
28 Jul 2021 | Hu Xiangwei appointed CEO; Song Henan appointed ED | Parent-group rotation |
20 Jul 2022 | Yan Jiong resigns as Chairman; Hu Xiangwei becomes Chairman | Parent-group rotation |
3 Aug 2023 | Zhu Yingxue appointed ED and CEO; Yang Jie and Wang Jin appointed EDs; Jiang Wei and Zhao Na cease | New management team; FY2023 RA notes "changes to directors and management" |
6 Jun 2025 | Hu Xiangwei retires; Zhu Yingxue appointed Chairman; ceases as CEO | AGM |
Major Shareholders
| Holder | Shares | % | Source |
|---|---|---|---|
Yunnan Energy Investment (HK) Co. Limited (beneficial owner) | 201,196,995 | 73.05 | 1H2026 IA |
Yunnan Provincial Energy Group Co., Ltd. (deemed, controlled corporation) | 201,196,995 | 73.05 | 1H2026 IA |
Public float | approx. 74,240,005 | approx. 26.95 | Analyst-derived |
Directors / insiders | Nil | 0.00 | 1H2026 IA |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Type | Relative positioning vs YEIG |
|---|---|---|---|
Distribution (medical equipment, SW China) | Sinopharm Group (medical device distribution arm) | National SOE distributor (HK-listed) | Orders of magnitude larger; national tender access |
Distribution | China Resources Pharmaceutical (medical device distribution) | SOE distributor (HK-listed) | Far larger; hospital channel depth |
Distribution | Shanghai Pharmaceuticals (device distribution) | SOE distributor | Far larger |
Distribution | Yunnan Baiyao / Yunnan provincial pharma-device distributors | Provincial players | Local competition for Yunnan hospital tenders |
Distribution (lab/analytical instruments) | Techcomp Instrument group (former parent business, now private) | Specialist instrument distributor/manufacturer | Retains the original Techcomp franchise and brand relationships |
Distribution | OEM direct sales (Thermo Fisher, Philips, GE HealthCare, Olympus China subsidiaries) | Manufacturers selling direct/through tier-1 dealers | Control pricing and dealer authorisations |
Supply Chain (commodity trading) | Xiamen C&D Inc. | SOE supply-chain giant (SSE-listed) | Vastly larger scale and financing |
Supply Chain | Xiamen Xiangyu Co. | SOE supply-chain giant | Vastly larger |
Supply Chain | Xiamen ITG Group | SOE supply-chain giant | Vastly larger |
Supply Chain | Wuchan Zhongda Group | Zhejiang SOE supply-chain group | Vastly larger |
Supply Chain (Yunnan energy/coal) | Yunnan Energy Investment Co., Ltd. (SZSE: 002053) — sister company in the same parent group | Provincial energy/gas | Potential overlap within group |
Supply Chain (silicon exports) | Hoshine Silicon, Yunnan-based silicon producers' own export desks | Producers selling direct | Can disintermediate traders |
Supply Chain (cross-border Laos/Vietnam) | Yunnan provincial trading SOEs (e.g., Yunnan International / Yunnan Construction-linked traders) | Provincial traders | Same border-trade corridors |
Peer Comparison FY2025
| Metric | YEIG FY2025 | Comment |
|---|---|---|
Revenue | HK$392.7M | YEIG sub-scale |
Revenue growth | −31.9% (FY2025); +3.5% (1H2026) | — |
Gross margin | 6.3% (10.8% 1H2026) | YEIG mix-driven upside |
Net margin | −0.2% | Fixed cost burden |
R&D intensity | 0% | Not a differentiator |
Recent Developments
Headcount was stable at 22.



